Bexar County Medical Society: Feb 2019 (Rao Lab)
February 28, 2019
UT Health SA Newsroom: Greehey researcher receives UT System’s Rising STARs award
February 26, 2019
Siyuan Zheng, PhD, assistant professor in the Department of Epidemiology and Biostatistics in the Long School of Medicine, has received a Rising STARs Award from the UT System. The award for early-career investigators comes with a $250,000 grant.
San Antonio Business Journal: SA gets small share of more than $90M in state cancer research money
February 22, 2019
The Cancer Prevention and Research Institute of Texas has awarded 54 new academic research, prevention and product development grants totaling nearly $96 million. San Antonio’s cut is $3 million. All three Alamo City grants will support research at UT Health San Antonio. They include a pair of $900,000 awards and one for $1.2 million. Dr. Yuzuru […]
UT Health Newsroom: UT Health San Antonio researchers awarded $3 million for cancer studies
February 22, 2019
Ewing sarcoma research Yuzuru Shiio, MD, PhD, of the Greehey Children’s Cancer Research Institute at UT Health San Antonio, was awarded $1.2 million to further studies of Ewing sarcoma, a pediatric bone and soft tissue cancer. The median age of Ewing sarcoma patients is 15 years, and more than half of patients are adolescents. Dr. […]
SA MD News: South Texas Pediatric Blood and Cancer Center: Serving South Texas’ Most Seriously Ill Children Through Cancer Care and Research
February 7, 2019
Expert pediatric cancer physicians and researchers at UT Health San Antonio are working to improve the lives of children with cancer, both for today and tomorrow. UT Health San Antonio, in partnership with the University Health System, offers advanced care for children battling cancer through the South Texas Pediatric Blood and Cancer Center. The team, […]
Pharmacy Times: Chemotherapies May Have Varying Long-Term Cardiovascular Risk
February 6, 2019
By studying the outcomes of more than 28,000 long-term childhood cancer survivors in the United States and Europe, researchers found that exposure to different anthracyclines results in variable long-term cardiovascular risk.
Science Daily: Do all chemotherapies have equal long-term heart risk? (Aune & Tomlinson Labs)
January 31, 2019
In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes. In a new study, published Jan. 31 in JAMA Oncology, researchers compared four chemotherapy drugs with the development of cardiomyopathy (abnormal heart muscle with impaired function) years after treatment.
Drug Discovery & Development: Do All Chemotherapies Have Equal Long-Term Heart Risk?
January 31, 2019
Gregory Aune, MD, PhD, of UT Health San Antonio, served on a team that found different chemotherapy drugs used to treat children with cancer appear to have different risks long term for cardiomyopathy (abnormal heart muscle with impaired function). The study was in more than 28,000 childhood cancer survivors. Credit: UT Health San Antonio In […]
UT Health SA Newsroom: Do all chemotherapies have equal heart risk long term?
January 31, 2019
Study of 28,000 childhood cancer survivors finds important differences In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes. In a new study, published Jan. 31 in JAMA Oncology, researchers compared four chemotherapy drugs with the development of cardiomyopathy (abnormal heart muscle with impaired function) years after treatment.
EurekAlert: Do all chemotherapies have equal long-term heart risk?
January 21, 2019
SAN ANTONIO — In long-term survivors of childhood cancer, cardiovascular disease is a leading cause of early death from non-cancer causes. In a new study, published Jan. 31 in JAMA Oncology, researchers compared four chemotherapy drugs with the development of cardiomyopathy (abnormal heart muscle with impaired function) years after treatment.